Table 4.
Association between Neonatal Growth and Comorbidities of Pregnancy by Supplementation Dose Group, Adjusted for Study and Race
| Control | 2000 IU | 4000 IU | p-value (overall) | p-value (2000 vs. control) | p-value (4000 vs. control) | NNT/H (2000 IU vs. control) | NNT/H (4000 IU vs. control) | |
|---|---|---|---|---|---|---|---|---|
| Neonatal birth weight, grams (SD) | 3233 (668) | 3382 (759) | 3231 (632) | 0.029 | > 0.05 | > 0.05 | -- | -- |
| Hypertensive Disorders of Pregnancy (N, %) | 9/110 (8.2) | 9/201 (4.5) | 4/193 (2.1) | 0.15 | 0.43 | 0.052 | NNT 27 | NNT 17 |
| Gestational Diabetes (N, %) | 8/110 (7.3) | 16/200 (8.0) | 10/191 (5.2) | 0.39 | 0.45 | 0.18 | NNH 138 | NNT 50 |
| Infection, any (N, %) | 45/110 (40.9) | 96/201 (47.8) | 75/193 (38.9) | 0.30 | 0.33 | 0.78 | NNH 15 | NNT 49 |
| Bacterial Vaginosis (N, %) | 12/110 (10.9) | 15/201 (7.5) | 9/193 (4.7) | 0.61 | 0.75 | 0.34 | NNT 23 | NNT 14 |
| Preterm Birth without Preeclampsia (N, %) | 14/107 (13.1) | 23/198 (11.6) | 26/192 (13.5) | 0.42 | 0.20 | 0.55 | NNT 69 | NNH 219 |
| Combined comorbidities (N, %) | 67/110 (60.9) | 125/201 (62.2) | 106/193 (54.9) | 0.43 | 0.97 | 0.30 | NNH 79 | NNT 17 |
NNT/H: Number Needed to Treat/Harm.
Excludes “Other” race due to small cell sizes. Continuous measures compared between dose groups using multivariable linear regression to adjust for study and participant race (excluding “Other”); pairwise comparisons against control performed using Dunnett's procedure. Dichotomous measures compared between dose groups using multivariable logistic regression to adjust for study and participant race (excluding “Other”).